Copyright
©The Author(s) 2022.
World J Gastroenterol. Dec 21, 2022; 28(47): 6619-6631
Published online Dec 21, 2022. doi: 10.3748/wjg.v28.i47.6619
Published online Dec 21, 2022. doi: 10.3748/wjg.v28.i47.6619
Ref. | Year | Country | Data source | N | Mortality (%) | Colostomy/ Ileostomy (%) | Major adverse event (%) | Readmission (%) | Surgical re-intervention (%) |
Peery et al[7] | 2018 | USA | National Inpatient Sample1 | 12.732 | 0.7 | 2.2 | 14.0 | 7.8 | 3.6 |
Zogg et al[8] | 2016 | USA | National Inpatient Sample1 | 68.4622 | - | - | 14.7 | - | 1.0 |
de Neree et al[9] | 2019 | Netherlands | Systematic Review | 139.897 | 0.7 | - | 24.0 | - | 0-8.9 |
Ma et al[10] | 2019 | USA | National Inpatient Sample1 | 262.843 | 0.8 | 25.3 | - | - |
Ref. | Year | Country | Endoscopic technique | Design | Comparison | Costs analyzed | Results |
Swan et al[19] | 2009 | Australia | EMR | Observational monocentric | Endoscopy vs surgery, Considering surgery without major complications | Direct costs including a 1-day hospital stay for EMR, Loss of utility not considered | EAC: $2051 pp, SAC: $9041 |
Jayanna et al[16] | 2016 | Australia | EMR | Observational multicentric | Endoscopy vs surgery, Considering surgery with and without complications | Direct costs including hospital stay and adverse events, 1st surveillance endoscopy | EAC: $4668 pp, SAC: $12720, If surgery 7.5% complications -> SAC: $45530 |
Law et al[17] | 2016 | USA | EMR | Decision analysis tree (hybrid Markov model) | Endoscopy (resection + surveillance, surgery if recurrence at 12 mo) vs laparoscopic surgery, Considering complications in both arms | Direct costs, Loss of utility considered, QALY, Sensitivity analysis | EAC: $5570 ppEndoscopy QALY: 9.64, SAC: $18717 pp, Surgery QALY: 9.58, Laparoscopy is cost-effective if complete EMR < 75.8%, EMR adverse events rate > 12% and laparoscopy cost < $14.000 |
Dahan et al[18] | 2019 | France | ESD | Observational monocentric | Endoscopy vs surgery, Considering complications in both arms | Direct costs including hospital stay and endoscopy costs | EAC: €3190, SAC: €8490 |
Buskermolen et al[13] | 2022 | Netherlands | Non-specified | Microsimulation screening analysis (MISCAN-colon) | Surgery vs attempted removal by an expert endoscopist, Considering complications in both arms | Direct costs, Loss of utility considered, QALY, Sensitivity analysis | EAC: €60.200, SAC: €72.700, Endoscopy QALY: 33.1/1000 individuals, Surgery QALY: 32.9/1000 individuals |
Complex polyp | Expert endoscopist | Reference endoscopy unit | |||||
SMSA score ≥ 12 (Level 4)[41] | BSG criteria[42] | BSG criteria[42] | |||||
BSG criteria[42] | 500 independent colonoscopies | Ensure that endoscopists undertake a sufficient number of procedures a year to maintain acceptable standards4 | |||||
Increased risk of malignancy | 100-125 EMR to obtain competence | ||||||
Kudo´s pit pattern V | A non-defined number1 of EMR procedures to maintain competence | ||||||
Paris 0-IIc/0-IIa+IIc | Time from referral to definitive management: < 8 wk | ||||||
LST-NG/LST-Gm (dominant nodule) | Fulfilling key performance indicators | ||||||
NICE 3/Sano III | Presence of recurrence/residual polyp at 12 mo < 10% | Geraghty et al[40] | |||||
Increased risk of incomplete resection/recurrence | Provided endoscopy list time for the additional workload with a dedicated list | ||||||
Size ≥ 40 mm | EMR perforation rate: < 2% | ||||||
Difficult location (ileocecal valve, appendix, diverticulum, dentate line) | Post-polypectomy bleeding rate: < 5% | Staff to include at least two endoscopists that can cover each other and endoscopy nurses with training in complex polypectomy | |||||
DOPyS2 | |||||||
Within an inflamed segment of the colon | ESGE3 curriculum for optical diagnosis[59] | ||||||
Prior failed resection attempt | Assessing competence: ≥ 80 % accuracy for identifying submucosal invasion in large (≥ 20 mm lesions), Maintaining competence: in vivo audit and review of at least 10 large (≥ 20 mm) lesions within a year | Equipment: including necessary snares and hemostatic devices | |||||
Non-lifting sign | |||||||
Increased risk of adverse events | Surgeons for discussion in the MDT and case of operative treatment of adverse events | ||||||
Cecum | |||||||
Endoscopist´s expertise | Robust referral system including administrative staff support and tools for virtual MDT | ||||||
ESGE criteria[21] | |||||||
Difficult location or poor access (ileocecal valve, periapendicular, anorectal junction) | |||||||
Prior failed resection attempts | |||||||
Non-lifting sign | |||||||
SMSA level 4 |
- Citation: Bustamante-Balén M. How to avoid overtreatment of benign colorectal lesions: Rationale for an evidence-based management. World J Gastroenterol 2022; 28(47): 6619-6631
- URL: https://www.wjgnet.com/1007-9327/full/v28/i47/6619.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i47.6619